Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Completed 4Active not recruiting 4Recruiting 3Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 1Other 1

Conditions

Tuberous Sclerosis 1Seizures 1Parasomnias 1Pain 1Nausea 1Chemotherapy-Induced Peripheral Neuropathy 1Cancer Pain 1Behavior 1Anxiety Disorders 1

Interventions

pembrolizumab 247Nivolumab 144Cyclophosphamide 137Cisplatin 137Paclitaxel 115Carboplatin 111Gemcitabine 100Radiotherapy 86Dexamethasone 84Docetaxel 79Ipilimumab 70atezolizumab 68Doxorubicin 63Fluorouracil 60Blood Specimen Collection 60Bevacizumab 59Etoposide 55fludarabine 54Rituximab 54Oxaliplatin 52Prednisone 51Lenalidomide 51Surveys and Questionnaires 50Cetuximab 47Standard of Care 46Capecitabine 46Radiosurgery 44Magnetic Resonance Spectroscopy 44lenvatinib 43durvalumab 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Cannabidiol × 1 year × Clear all
NCT05864846 2026-04-27

EpiCom

Jazz Pharmaceuticals

Phase 4 Completed
79 enrolled

Behavior, Seizures, Tuberous Sclerosis

NCT06533657 2026-04-21

UTOPIA-1

ZYUS Life Sciences Inc.

Phase 2 Completed
11 enrolled

Cancer Pain

NCT05388058 2026-01-16

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Mayo Clinic

Phase 2 Completed
40 enrolled 15 charts
OtherOther solid neoplasm

Chemotherapy-Induced Peripheral Neuropathy

NCT03948074 2025-09-10

CAFCARS

British Columbia Cancer Agency

Phase 2 Completed
91 enrolled

Anxiety Disorders, Nausea, Pain, Parasomnias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡